Strive (ASST) has drawn fresh attention after recent trading showed a sharp contrast between its positive 1 day and 7 day returns, and its weaker performance over the past month and past 3 months.

At a latest share price of $13.00, Strive has seen a short burst of positive momentum with its 1 day and 7 day share price returns. However, its 1 year and 3 year total shareholder returns remain sharply weaker, indicating that recent strength is emerging from a much softer long term trend.

If this kind of rebound has you thinking about what else could be setting up for a turn, it could be worth scanning the market with the 18 top founder-led companies

Given Strive’s recent bounce against a steep multi year decline, the key issue now is whether the current share price still compensates you for the risks. How does the valuation stack up after this move?

Preferred Price-to-Book Multiple of 1.5x: Is It Justified?

For Strive, the clearest valuation signal right now comes from its price-to-book ratio. At a P/B of 1.5x, the stock trades below both its peer group average of 2.9x and the broader US Medical Equipment industry average of 2.3x.

The P/B multiple compares the market value of the company to its book value, or net assets on the balance sheet. For asset focused businesses like Strive, this can be a useful cross check on whether investors are paying a premium or a discount to the underlying equity in the business.

With Strive currently reporting losses and a reported return on equity of a decline of 63.57%, a lower P/B multiple can signal that the market is cautious about the company’s ability to turn its balance sheet into profitable growth. However, the fact that the ratio sits meaningfully below both industry and peer averages suggests the stock is being priced more conservatively than many of its closest comparables.

Compared to the US Medical Equipment industry average P/B of 2.3x and the peer average of 2.9x, Strive’s 1.5x multiple stands out as materially lower. That gap reflects a market view that is less willing to pay up for its assets than for peers, despite forecasts for revenue growth of 19.2% per year and expectations that the company could move into profitability within three years.

Result: Price-to-book of 1.5x (UNDERVALUED).

However, Strive’s sharp 1 year and 3 year total shareholder return declines, together with a reported net loss of $700.519 against revenue of $7.071, could challenge any recovery narrative.

Next Steps

If this mixed picture around Strive has you on the fence, it makes sense to review the full set of data and sentiment now and then weigh up the 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Strive?

If Strive has you rethinking your portfolio, this is the moment to widen your watchlist and spot opportunities that others might be overlooking.

• Target steadier returns by checking companies that appear more conservatively positioned in our 81 resilient stocks with low risk scores.
• Hunt for potential value opportunities where quality and pricing intersect using the 50 high quality undervalued stocks.
• Strengthen your income focus by assessing stocks highlighted in the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.